本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下属上海上药新亚药业有限公司 （以下简称"上药新亚"）的注射用头孢唑林钠（以下简称"该药品"）收到国家药品监督管理局（以下简 称"国家药监局"）颁发的《药品补充申请批准通知书》（通知书编号：2026B01286、2026B01287）， 该药品通过仿制药质量和疗效一致性评价。 一、该药品基本情况 药品名称：注射用头孢唑林钠 剂型：注射剂 规格：0.5g、1.0g 注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感 染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。2024年7月，上药 新亚就该药品仿制药一致性评价向国家药监局提出申请并获受理。截至本公告日，公司针对该药品的一 致性评价已投入研发费用约为人民币332.41万元。 截至本公告日，中国境内该药品的主要生产厂家为广东金城金素制药有限公司、成都倍特药业股份有限 公司、齐鲁安替制药有限公司、浙江 ...

（编辑 袁冠琳） 证券日报网讯 3月17日，上海医药发布公告称，公司下属上海上药新亚药业有限公司的注射用头孢唑林 钠收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知书编号：2026B01286、 2026B01287），该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Shenyang New Asia Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of perioperative infections [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium has received approval from the National Medical Products Administration [1] - The approval notice includes notification numbers 2026B01286 and 2026B01287 [1] - The drug has successfully passed the consistency evaluation of quality and efficacy for generic drugs [1]

根据国家相关政策，通过一致性评价的品种在医保支付及医疗机构采购等领域将获得更大的支持力度。 因此上药新亚的注射用头孢唑林钠通过仿制药一致性评价，有利于扩大该药品的市场份额，提升市场竞 争力，同时为公司后续产品开展一致性评价工作积累了宝贵的经验。 注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感 染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。2024年7月，上药 新亚就该药品仿制药一致性评价向国家药监局提出申请并获受理。截至本公告日，公司针对该药品的一 致性评价已投入研发费用约为人民币332.41万元。 上海医药（601607）(02607)公布，近日，公司下属上海上药新亚药业有限公司(以下简称"上药新亚")的 注射用头孢唑林钠收到国家药品监督管理局颁发的《药品补充申请批准通知书》(通知书编号： 2026B01286、2026B01287)，该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd., has received approval for its injectable Cefazolin Sodium, which has passed the consistency evaluation for generic drugs, enhancing its market competitiveness and potential market share [1] Group 1: Product Approval - The injectable Cefazolin Sodium received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration [1] - The drug is indicated for treating infections caused by sensitive bacteria, including respiratory, urinary, skin, soft tissue, bone, joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for perioperative infection prevention [1] Group 2: Research and Development Investment - The company has invested approximately RMB 3.3241 million in the research and development of this drug's consistency evaluation [1] Group 3: Market Implications - Products that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, which is expected to expand the market share of the injectable Cefazolin Sodium [1] - The successful evaluation also provides valuable experience for the company in conducting future consistency evaluations for other products [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感 染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。 格隆汇3月17日丨上海医药(601607.SH)公布，公司下属上海上药新亚药业有限公司（称"上药新亚"）的 注射用头孢唑林钠（称"该药品"）收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知 书编号：2026B01286、2026B01287），该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd. (referred to as "Shenyang Pharmaceutical"), received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of infections during surgery [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) is facing multiple challenges, including tax payment issues, stock manipulation by its actual controller Zhao Yeqing, and declining financial performance, raising concerns about the company's future stability and management effectiveness [2][9]. Group 1: Tax Issues - Jincheng Jinsu Pharmaceutical Co., Ltd. and its subsidiary Guangdong Landu Pharmaceutical Co., Ltd. were required to pay a total of 21.5968 million yuan in back taxes and penalties due to tax issues from 2017 to 2018 [3]. - The tax payments have been completed as of the announcement date, and a supplementary agreement was signed to revise tax liability clauses related to the tax recovery [5]. Group 2: Stock Manipulation - Zhao Yeqing, the actual controller of Jincheng Pharmaceutical, was involved in stock manipulation from August 2017 to February 2020, using 104 accounts to trade the company's stock, which led to a fine and a four-year market ban [7][8]. - The manipulation involved significant trading activity, with 1.19 billion shares bought and 1.07 billion shares sold, resulting in a loss of 7.392 million yuan for the involved accounts [8]. Group 3: Financial Performance - Jincheng Pharmaceutical's financial performance has been declining, with a revenue of 35.38 billion yuan in 2023, a growth rate of only 0.93%, and a net profit decrease of 36.09% to 1.75 billion yuan [9]. - In the first three quarters of 2025, the company reported a revenue of 19.32 billion yuan, down 23.19%, and a net profit of 31.5771 million yuan, down 79.1% [9]. - The company experienced a significant decline in its gross margin to 36.23%, a decrease of 3.9 percentage points, and a net margin of 1.74%, down 4.71 percentage points compared to the previous year [9].